



31 March 2011

**Immunodiagnostic Systems Holdings plc
("IDS" or "the Company")**

**Two new specialist assays launched for use on the IDS-iSYS and
IGF-I cleared for sale in the USA**

Immunodiagnostic Systems Holdings plc, a leading producer of diagnostic testing kits for the clinical and research markets, announces the launch of two new automated assays for use on the IDS-iSYS Immunoassay System:

- Ostase® Bone Specific Alkaline Phosphatase (BAP) assay
- Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) assay

These launches bring the IDS-iSYS product range to a total of 9 specialist immunoassays.

The IDS-iSYS Ostase® BAP kit, the latest addition to the IDS-iSYS Bone Panel, is a fully automated assay for the quantitative determination of bone specific alkaline phosphatase, a bone formation marker, in human serum and plasma. Measurement of BAP is useful in the management of metabolic bone disease, such as postmenopausal osteoporosis.

The IDS-iSYS IGFBP-3 kit completes the IDS-iSYS Growth Panel and measures IGFBP-3 in human serum and plasma. Measurement of IGFBP-3, when used alongside the results obtained using the IDS-iSYS human Growth Hormone (hGH) and Insulin-like Growth Factor-I (IGF-I) assays, is useful in the diagnosis of growth hormone-related disorders and the monitoring of treatment.

Clearance has been received from the US Food and Drugs Administration (FDA) for the IDS-iSYS IGF-I controls, enabling the automated IGF-I assay to be sold in the USA.

Ian Cookson, CEO of IDS, said: "The extension of the IDS-iSYS product range makes our system even more attractive to laboratory managers where it can play a greater role in their testing routines".

IDS will provide a trading update for the year ended 31 March 2011 on Wednesday, 6 April 2011.

Immunodiagnostic Systems Holdings plc
Ian Cookson, Chief Executive Officer
Paul Hailes, Finance Director

Tel: 0191 519 0660

Walbrook PR Ltd
Paul McManus

Tel: 020 7933 8787
Mob: 07980 541 893

paul.mcmanus@walbrookpr.com